排序方式: 共有36条查询结果,搜索用时 15 毫秒
21.
肝硬变与原发性肝癌的相关性已被人们所重视,有报告30%~40%的肝硬变患者并发原发性肝癌,但肝硬变并发原发性肝癌与标志肝病进展的Child分级的关系,目前报道较少。本文对近四年收治的120例肝炎后肝硬变并发原发性肝癌患者,采用Child分级的方法分析,试图探讨原发性肝癌与Child分级的关系,以加深对肝炎后肝硬变原发性肝癌的临床认 相似文献
22.
23.
104例肝炎后肝硬化患者胃镜检查结果及其临床意义 总被引:25,自引:1,他引:24
为探讨肝炎后肝硬化患者食管及胃粘膜的改变,我们对104例肝炎后肝硬化患者进行了胃镜检查,对门脉高压性胃病(PHG)进行诊断,并对照其与消化道出血的发生率、B超门脉测量、肝功能等关系,以指导临床及时发现门脉高压性胃病及判断肝炎后肝硬化出血原因,采取合理的治疗。一、一般资料本组104例肝炎后肝硬化均为我院1995年~1996年住院患者,全部病例于入院1周内做胃镜检查,诊断符合第五次全国病毒性肝炎会议制定的诊断标准。其中,男80例,女24例,平均年龄47.4±11.7(15~76)岁,有家族性肝炎史者… 相似文献
24.
目的:观察非器官特异性自身抗体对慢性丙型肝炎抗病毒疗效的影响。方法:回顾性分析慢性丙型肝炎合并自身抗体阳性患者32例,以同期住院的年龄及性别相匹配的自身抗体阴性患者32例作为对照,观察其治疗结束病毒应答(ETVR)、复发(Relapse)及持续病毒应答(SVR)。结果:观察组及对照组ETVR、SVR分别为78.1%、71.9%及59.4%、53.1%。具有统计学差异。结论:自身抗体阴性的慢性丙型肝炎患者对干扰素联合利巴韦林治疗比合并自身抗体阳性患者具有更好的疗效。 相似文献
25.
26.
27.
重型病毒性肝炎上消化道粘膜病变机理探讨 总被引:2,自引:0,他引:2
本文用胃镜观察了99例重型病毒性肝炎患者的上消化道粘膜变化。急重型、亚重型肝炎患者83.3%有急性胃粘膜病变,表现为胃壁粘膜抓痕样条状充血、水肿、散在新鲜出血点等。慢性重型肝炎患者以肝硬化伴门脉高压者胃粘膜病变较多,发生率也高。急重型肝炎和亚急重型肝炎的机理可能与肿瘤坏死因子的作用、凝血因子合成障碍、患者的低氧血症及酸碱失衡有关。慢性重型肝炎患者除上述因素外,可能还存在内毒素的作用,门脉的高压作用和高胃泌素血症等。 相似文献
28.
本研究借助胃镜检查取材,对118例HIV感染者/AIDS患者的上消化道机会性病原感染进行检测,并与外周血CD4^+细胞计数水平进行对比分析,以便为临床的诊断和治疗提供依据。 相似文献
29.
目的:探讨窄带成像(NBI)技术与染色技术对胃部疾病的诊断价值。方法:对328例常规内镜检查有病灶者行NBI检查、亚甲蓝染色检查、亚甲蓝醋酸染色检查,观察3组检查方法胃黏膜腺管形态及微血管结构变化,进行病变显示清晰度评分,评价病变性质,并与术后病理检查结果进行比较。结果:NBI组腺管结构清晰度评分优于亚甲蓝染色组(χ2=16.58,P〈0.05),但与亚甲蓝醋酸染色组比较,差异无统计学意义(χ2=2.31,P〈0.05);微血管结构显示评分NBI组显著高于亚甲蓝染色组及亚甲蓝醋酸染色组(χ2=18.33,P〈0.05;χ2=16.74,P〈0.05);NBI组镜下诊断与病理诊断符合率(83.8%)显著高于亚甲蓝染色组(73.2%)(χ2=17.12,P〈0.05),但与亚甲蓝醋酸染色组(85.4%)比较,差异无统计学意义(χ2=2.74,P〉0.05)。结论:NBI诊断胃部疾病效果确切,亚甲蓝醋酸染色诊断效果与NBI相近,值得推广。 相似文献
30.
目的 观察重组人干扰素(IFN)α-1b和重组人IFN α-1b联合拉米夫定(LAM)治疗HBeAg阳性慢性乙型肝炎患者的疗效,并分析影响疗效的因素.方法收集HBeAg阳性慢性乙型肝炎患者111例,其中49例为单药治疗组,给予重组人IFN α-1b治疗(50μg/次,隔日1次,肌肉注射),62例为联合治疗组,给予重组人IFN α-1b(50μg/次,隔日1次,肌肉注射)加LAM(100 mg/d,口服)联合治疗,疗程为6~12个月或>12个月.在治疗前、治疗后3、6、9、12、18个月及治疗结束时比较两组患者的HBV DNA低于检测下限率、HBeAg及HBsAg血清转换率.同时检测LAM的耐药变异情况.采用t检验和x2检验进行统计分析.结果 (1)治疗3、6、9、12、18个月后,单药治疗组HBeAg血清学转换率分别为6.1%、8.2%、14.3%、28.6%、36.7%,联合治疗组HBeAg血清学转换率分别为1.6%、8.1%、14.5%、29.0%、38.7%,两组比较,x2值分别为1.602、0.000、0.001、0.003、1.500,P值均>0.05,差异均无统计学意义;(2)治疗3、6、9、12、18个月后,单药治疗组HBV DNA低于检测下限率分别为0、8.2、36.7%、53.1%、57.1%,联合治疗组HBV DNA低于检测下限率分别为30.7%、66.1%、79.0%、83.9%、88.7%,两组比较,x2值分别为25.205、38.150、20.465、12.073、14.459,P值均<0.05,差异有统计学意义;(3)单药治疗组,男性患者组和女性患者组HBeAg血清学转换率分别为34.5%、40.0%两组比较,差异无统计学意义.年龄≥40岁和<40岁的患者的HBeAg血清转换率分别为50.0%、34.9%,两组比较,差异无统计学意义.HBV DNA≥6 log10拷贝/ml和HBV DNA<6 log10拷贝/ml的患者HBeAg血清转换率分别为52.4%、25.0%两组比较,x2=3.871,P<0.05,差异有统计学意义.结论 (1)适当延长疗程有利于HBeAg阳性慢性乙型肝炎患者HBeAg血清学的转换;(2)联合治疗组HBV DNA低于检测下限率高于单药治疗组;(3)单药治疗组中,高HBVDNA载量患者HBeAg血清转换率比低HBV DNA载量患者低.Abstract: Objective To compare the efficacy and safety of interferon α -1b and interferon α-1b combined with lamivudine in the treatment of HBeAg positive chronic hepatitis B (CHB), to analyze the impact of variable factors on the efficacy, and to investigate the individualized anti-viral regimen for CHB patients. Methods 111 CHB patients were enrolled and randomly divided into two groups. Group A:patients received interferon α -1b (49 patients, 50 μg I. M., qod. ), Group B: interferon α -1b (idem)combined with lamivudine for 6-12 months or longer(62 patients, 100 mg, P. O., q. d. ). Results (1) The HBeAg seroconversion rates of treatment by 12 and 18 months were 28.6% and 36.7% in group A, 29.0% and 38.7% in group B, respectively, no significant difference found between the two groups at the end of treatment( x2 = 0.003, P > 0.05; x2 = 1.500, P > 0.05). (2) The HBV DNA undetectable rates of treatment by 6months, 12 months and 18 months were 8.2%, 53.1% and 57.1% in group A,66.1%, 83.9% and 88.7% in group B, respectively, still no significant difference existed between the two groups ( x2 = 38.150, P < 0.05;x2 = 12.073, P < 0.05, x2 = 14.459, P < 0.05). (3) In group A, the HBeAg seroconversion rates for male and female patients were 34.5% and 40.0% respectively, no significant difference found between. As regard ages the rates were 34.9% and 50.0% for patients younger or more than 40 years of age, no significant difference existed between. The HBeAg seroconversion rate was higher in patients with lower baseline serum HBV DNA loads (< 6 log10copies/ml). (4) The rates of patients with fever and blood abnormality were 36.7% and 34.7% in group A, 32.3% and 27.4% in group B, respectively. The total incidences of adverse events were similar between group A and B ( x2 = 0.244, P > 0.05; x2 = 0.682, P > 0.05). (5) The ratio of drug resistance in group B was only 1.6%. Conclusion The adverse events of interferon α -1b treatment for CHB are low and mild. The HBeAg seroconversion rate persistently raises with the extension of interferon α -1b treatment course. The HBV DNA undetectable rate of interferon α -1b combined with lamivudine is significantly higher than that of interferon α -1b and the drug resistance of lamlvudine can be reduced obviously by combination therapy. 相似文献